Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Other hematologic neoplasm 1Myeloid 1Lymphoid 1Dermatologic 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Graft vs Host Disease 1

Interventions

Cyclophosphamide 344Rituximab 307Vincristine 159Doxorubicin 156venetoclax 154Specimen Handling 154fludarabine 153Prednisone 151Biopsy 124Magnetic Resonance Spectroscopy 119obinutuzumab 116Lenalidomide 110Dexamethasone 105Cytarabine 98ibrutinib 96Etoposide 92fludarabine phosphate 87Methotrexate 85acalabrutinib 78Bendamustine Hydrochloride 73zanubrutinib 72blinatumomab 64pembrolizumab 62CT-P10 60Gemcitabine 51Nivolumab 45Calcium Dobesilate 45glofitamab 44Mercaptopurine 44prednylidene 42

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
LDP-02 × Lymphoid × 1 year × Clear all
NCT06815003 2025-06-27

Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

City of Hope Medical Center

Phase 2 Recruiting
35 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡